Esophageal cancer: CT, endoscopie US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review

Radiology

Volumn 236, Issue 3, 2005, Pages 841-851

  Westerterp, Marinke ^a   Van Westreenen, Henderik L ^b   Reitsma, Johannes B ^a   Hoekstra, Otto S ^c   Stoker, Jaap ^a   Fockens, Paul ^a   Jager, Pieter L ^b   Van Eck Smit, Berthe L F ^a   Plukker, John T M ^b   Van Lanschot, J Jan B ^a   Sloof, Gerrit W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; VINCRISTINE SULFATE;

ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG RESPONSE; EMBASE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; HUMAN; INTERMETHOD COMPARISON; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SYSTEMATIC REVIEW;

ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 23844455598     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2363041042     Document Type: Review

References (56)

1. Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest 1998;113(suppl 1):112S-119S.
2. Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D. An audit of the treatment of cancer of the oesophagus. Gut 1994;35:941-945.
3. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001;72:306-313.
4. Chung SC, Stuart RC, Li AK. Surgical therapy for squamous-cell carcinoma of the oesophagus. Lancet 1994;343:521-524.
5. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990;77:845-857.
6. Daly JM, Fry WA, Little AG, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190:562-572.
7. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733.
8. Wolfman NT, Scharling ES, Chen MY. Esophageal squamous carcinoma. Radiol Clin North Am 1994;32:1183-1201.
9. Van Dam J. Endosonographic evaluation of the patient with esophageal cancer. Chest 1997;112(suppl 4):184S-190S.
10. Fockens P, Manshanden CG, van Lanschot JJ, Obertop H, Tytgat GN. Prospective study on the value of endosonographic follow-up after surgery for esophageal carcinoma. Gastrointest Endosc 1997;46:487-491.
11. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinomas. II. A critical view of radiotherapy. Br J Surg 1980;67:457-461.
12. Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996; 83:107-111.
13. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003;44:224-239.
14. Cochrane Methods Working Group on Systematic Review of Screening and Diagnostic Tests. Recommended methods. http://www .cochrane.org/docs/sadtdoc1. htm. Updated June 6, 1996. Accessed July 30, 2003.
15. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-1316.
16. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 1993;13:313-321.
17. Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994;120:667-676.
18. Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995;48:119-130.
19. Helmberger H III, Baum U, Dittler HJ, et al. Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy. Eur J Radiol 1996;23:107-110.
20. Walker SJ, Allen SM, Steel A, Cullen MH, Matthews HR. Assessment of the response to chemotherapy in oesophageal cancer. Eur J Cardiothorac Surg 1991;5:519-522.
21. Griffith JF, Chan AC, Chow LT, et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 1999;72:678-684.
22. Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:1026-1032.
23. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer: a comparison of different analytical methods. Mol Imaging Biol 2003;5:337-346.
24. Nousbaum JB, Robaszkiewicz M, Cauvin JM, Calament G, Gouerou H. Endosonography can detect residual tumour infiltration after medical treatment of oesophageal cancer in the absence of endoscopic lesions. Gut 1992;33:1459-1461.
25. Rice TW, Boyce GA, Sivak MV, Adelstein DJ, Kirby TJ. Esophageal carcinoma: esophageal ultrasound assessment of preoperative chemotherapy. Ann Thorac Surg 1992;53:972-977.
26. Hordijk ML, Kok TC, Wilson JH, Mulder AH. Assessment of response of esophageal carcinoma to induction chemotherapy. Endoscopy 1993;25:592-596.
27. Dittler HJ, Fink U, Siewert JR. Response to chemotherapy in esophageal cancer. Endoscopy 1994;26:769-771.
28. Giovannini M, Seitz JF, Thomas P, et al. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Endoscopy 1997;29:4-9.
29. Bowrey DJ, Clark GW, Roberts SA, et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 1999;3:462-467.
30. Laterza E, de Manzoni G, Guglielmi A, Rodella L, Tedesco P, Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999;67:1466-1469.
31. Zuccaro G Jr, Rice TW, Goldblum J, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999;94:906-912.
32. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66: 827-831.
33. Hirata N, Kawamoto K, Ueyama T, Masuda K, Utsunomiya T, Kuwano H. Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced esophageal cancer. AJR Am J Roentgenol 1997;169:485-491.
34. Chak A, Canto MI, Cooper GS, et al. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 2000;88:1788-1795.
35. Willis J, Cooper GS, Isenberg G, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002;55:655-661.
36. Isenberg G, Chak A, Canto MI, et al. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 1998;48:158-163.
37. Nakamura R, Obara T, Katsuragawa S, et al. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after radiotherapy. Radiat Med 2002; 20:181-186.
38. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403-1406.
39. McAteer D, Wallis F, Couper G, et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999;72:525-529.
40. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
41. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002;4:301-310.
42. Kato H, Kuwano H, Nakajima M, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184:279-283.
43. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-432.
44. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-309.
45. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
46. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368.
47. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
48. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994;73:2680-2686.
49. Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 9th ed. Tokyo, Japan: Kanehara, 1999.
50. Roubein LD, DuBrow R, David C, et al. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. Endoscopy 1993;25:587-591.
51. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-1782.
52. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002;43:1304-1309.
53. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-1777.
54. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995;196:167-173.
55. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731-743.
56. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995;221:677-683.